Skip to main content

imnn-001

Generic: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector IMNN-001

imnn-001: 3 clinical trials tracked.

imnn-001 evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about imnn-001, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (3)

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025·Phase 3·IMNN
Recruiting

Primary endpoint: Overall Survival

InterventionalRandomizedopen500 targetStarted 2025-07Completion 2032-108 sites · United StatesImunon

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981·Phase 1/Phase 2·IMNN
Recruiting

Primary endpoint: Minimal Residual Disease

InterventionalRandomizedopen30 targetStarted 2023-02Completion 2028-084 sites · United StatesImunon

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03393884·Phase 1/Phase 2·IMNN
Active, not recruiting

Primary endpoint: PFS

InterventionalRandomizedopen130 targetStarted 2018-09Completion 2026-0521 sites · Canada, United StatesImunon